Table 3 Baseline demographic characteristics of the patientsa
Characteristics | Study (n= 53) | Control (n= 53) | P value |
|---|---|---|---|
Age, yearsb | 70 (64 to 78) | 72 (65 to 82) | 0.3729 |
Sex | |||
Males, n (%) | 32 (60.4) | 29 (54.7) | 0.6826 |
Females, n (%) | 21 (39.6) | 24 (45.3) | 0.7726 |
Weight, kg | 59.3 ± 12.5 | 61.2 ± 11.7 | 0.4243 |
Height, cm | 166.2 ± 11.4 | 167.7 ± 10.4 | 0.4749 |
APACHE II scoreb | 19.5 (17 to 25) | 20 (16 to 23) | 0.5291 |
SOFA scoreb | 5.5 (4 to 9) | 6 (4 to 8) | 0.7991 |
MODS scoreb | 4 (3 to 6) | 4 (3 to 5) | 0.6106 |
Lactate, mmol/Lb | 3.75 (2.9 to 4.65) | 3.7 (2.8 to 4.3) | 0.7181 |
Blood glucose, mg/dLb | 103 (89 to 149) | 102 (87 to 125) | 0.6109 |
Temperature, °Cb | 39.4 (38.2 to 39.8) | 38.9 (37.2 to 39.5) | 0.0780 |
GCS score | 10.1 ± 2.2 | 10.8 ± 2.1 | 0.1661 |
White blood cells, 1 × 109 cells/L | 19.3 ± 0.9 | 20.7 ± 0.7 | 0.4187 |
Platelets, 1 × 109 cells/Lb | 198 (144 to 259) | 211 (178 to 256) | 0.3580 |
Serum creatinine, mg/dLb | 1.15 (0.9 to 1.6) | 0.9 (0.8 to 1.3) | 0.9088 |
Total bilirubin, mg/dLb | 0.9 (0.7 to 1.3) | 0.8 (0.7 to 1.5) | 0.7739 |
Serum Na, mEq/Lb | 139 (133 to 145) | 135 (137 to 144) | 0.9053 |
Serum K, mEq/L | 3.9 ± 0.7 | 4.0 ± 0.8 | 0.6718 |
Patients supported with MV, n (%)c | 1 (1.9) | 2 (3.8) | 0.5172 |
Patients treated with sedatives, n (%) | 3 (5.7) | 5 (9.4) | 0.1280 |
Baseline comorbidities, n (%) | |||
Recent surgery (< 3 months) | 6 (11.3) | 9 (16.9) | 0.4008 |
History of alcoholism | 10 (18.9) | 8 (15.1) | 0.6027 |
Asthma | 12 (22.6) | 17 (32.1) | 0.2705 |
Diabetes | 10 (18.9) | 9 (16.9) | 0.7988 |
COPD | 11 (20.75) | 12 (22.6) | 0.8122 |
Cancer | 4 (7.5) | 4 (7.5) | 0.6425 |
Thromboembolism | 1 (1.9) | 1 (1.9) | 0.7525 |
History of illicit drug use | 4 (7.5) | 2 (3.8) | 0.6425 |
Primary source of infection, n (%) | |||
Lungs | 38 (71.7) | 33 (62.3) | 0.2893 |
Abdomen | 6 (11.3) | 8 (15.1) | 0.5311 |
Urinary tract | 4 (7.6) | 2 (3.7) | 0.1980 |
Other | 5 (9.4) | 10 (18.9) | 0.0815 |